A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn (Pralatrexate) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Trial Profile

A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn (Pralatrexate) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Folinic acid (Primary) ; Pralatrexate (Primary)
  • Indications Mucositis; T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
    • 18 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 11 Dec 2014 Planned number of patients changed from 20 to 37, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top